This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Novus And Verenium Introduce The Newest Addition To Novus's Enzyme Solutions Portfolio: CIBENZA® PHYTAVERSE™

Stocks in this article: VRNM

ST. LOUIS and SAN DIEGO, July 26, 2013  /PRNewswire/ -- Novus International, Inc. and Verenium Corporation (Nasdaq: VRNM) today announced the name of their new phytase enzyme product, CIBENZA ® PHYTAVERSE .  This new innovative phytase is specifically designed to unlock more of the hidden nutritional value in phytate for improved animal growth and well-being. 


The two companies, which entered into a strategic partnership in 2011, designed CIBENZA ® PHYTAVERSE to have specific performance characteristics that offer significant advantages over current phytase products.  These performance characteristics include:

  • High in vivo activity under gastric conditions for sustained performance
  • Improved activity at low substrate concentrations to maximize phytate hydrolysis
  • High gastric stability for activity throughout the upper gastrointestinal tract
  • High intrinsic thermotolerance and pelleting stability
  • Improved bioavailability due to the elimination of the need for thermo protective coatings

"We're excited to bring this new enzyme solution to the market," said Gary Hayen, Global Director Fermentation Products at Novus.  "The partnership with Verenium is allowing us to offer our customers the synergy of cutting-edge enzyme technology and nutrition solutions knowledge which makes CIBENZA ® PHYTAVERSE a valuable asset for today's feed industry."

Animal trial results have demonstrated the superior performance characteristics that CIBENZA ® PHYTAVERSE provides, based on standard metrics such as weight gain, feed conversion ratios and phosphorus mineralization (tibia ash) versus other available phytase products.  These results indicate that inclusion of CIBENZA ® PHYTAVERSE in monogastric diets can provide improved nutrition and economics to the animal feed industry.

"By combining Novus's animal nutrition expertise and extensive industry knowledge with over 15 years of experience in developing high-performance phytase products at Verenium, together we've been able to create a next-generation phytase that exhibits superior performance characteristics over those marketed today," said David Weiner, Vice President of R&D Strategy and Partnerships at Verenium. "These important characteristics allow the animal to more efficiently utilize the phosphorus and other nutrients necessary for improved animal health and nutrition, and can provide producers an increased return on investment."

Novus and Verenium expect to launch this product in certain geographical regions beginning in 2013.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs